Question

I am a breastfeeding mother and i want to know if it is safe to use Cosmegen Lyovac? Is Cosmegen Lyovac safe for nursing mother and child? Does Cosmegen Lyovac extracts into breast milk? Does Cosmegen Lyovac has any long term or short term side effects on infants? Can Cosmegen Lyovac influence milk supply or can Cosmegen Lyovac decrease milk supply in lactating mothers?

Cosmegen Lyovac lactation summary

Cosmegen Lyovac is dangerous in breastfeeding
  • DrLact safety Score for Cosmegen Lyovac is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of Cosmegen Lyovac may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that Cosmegen Lyovac may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using Cosmegen Lyovac .
  • Usage of Cosmegen Lyovac is in contradiction to breastfeeding hence if it is must to use Cosmegen Lyovac and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Cosmegen Lyovac usage in lactation

Drug is cleared from the body in 7 elimination half-lives. Resuming breastfeeding is likely safe after 10 days of pumping-and-dumping.

Answer by DrLact: About Cosmegen Lyovac usage in lactation

No information is available on the use of Cosmegen Lyovac during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during Cosmegen Lyovac therapy and for 14 days after the last dose.

Alternate Drugs

Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Dactinomycin(Dangerous)
Paclitaxel(Dangerous)
Gemcitabine(Dangerous)
Nivolumab(Unsafe)
Hydroxyurea(Low Risk)
Fluorouracil(Dangerous)
Vinblastine(Dangerous)
Etoposide(Dangerous)
Alemtuzumab(Low Risk)
Docetaxel(Dangerous)
Pazopanib(Unsafe)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Rituximab(Low Risk)
Vinorelbine(Dangerous)
Cyclophosphamide(Dangerous)
Bevacizumab(Low Risk)
Dacarbazine(Dangerous)
Cisplatin(Unsafe)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Letrozole(Dangerous)
Imatinib(Unsafe)
Erlotinib(Unsafe)
Exemestane(Dangerous)
Dasatinib(Unsafe)
Dactinomycin(Dangerous)
Nilotinib(Unsafe)
Vincristine(Dangerous)
Ipilimumab(Unsafe)
Tamoxifen(Dangerous)
Cetuximab(Unsafe)
Mitoxantrone(Dangerous)
Carboplatin(Dangerous)
Dactinomycin(Dangerous)
Dactinomycin(Dangerous)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.